Cargando…

De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysis

BACKGROUND: The role of adjuvant chemotherapy in gastric neuroendocrine neoplasms (GNEC) has not been well clarified yet. The study was designed to investigate the potential effect of adjuvant chemotherapy in stage I–II GNEC patients and construct a predictive nomogram. METHOD: Stage I–II GNEC patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Danwei, Xie, Yangyang, Li, Xiaowen, Ni, Zhongkai, Shi, Jinbo, Huang, Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163728/
https://www.ncbi.nlm.nih.gov/pubmed/37149679
http://dx.doi.org/10.1186/s12957-023-03029-2
_version_ 1785037943668211712
author Du, Danwei
Xie, Yangyang
Li, Xiaowen
Ni, Zhongkai
Shi, Jinbo
Huang, Hai
author_facet Du, Danwei
Xie, Yangyang
Li, Xiaowen
Ni, Zhongkai
Shi, Jinbo
Huang, Hai
author_sort Du, Danwei
collection PubMed
description BACKGROUND: The role of adjuvant chemotherapy in gastric neuroendocrine neoplasms (GNEC) has not been well clarified yet. The study was designed to investigate the potential effect of adjuvant chemotherapy in stage I–II GNEC patients and construct a predictive nomogram. METHOD: Stage I–II GNEC patients were included in the Surveillance, Epidemiology, and End Results (SEER) database and divided into chemotherapy and no-chemotherapy groups. We used Kaplan–Meier survival analyses, propensity score matching (PSM), and competing risk analyses. The predictive nomogram was then built and validated. RESULTS: Four hundred four patients with stage I–II GNEC were enrolled from the SEER database while 28 patients from Hangzhou TCM Hospital were identified as the external validation cohort. After PSM, similar 5-year cancer-specific survival was observed in two groups. The outcomes of competing risk analysis indicated a similar 5-year cumulative incidence of cancer-specific death (CSD) between the two cohorts (35.4% vs. 31.4%, p = 0.731). And there was no significant relation between chemotherapy and CSD in the multivariate competing risks regression analysis (HR, 0.79; 95% CI, 0.48–1.31; p = 0.36). Furthermore, based on the variables from the multivariate analysis, a competing event nomogram was created to assess the 1-, 3-, and 5-year risks of CSD. The 1-, 3-, and 5-year area under the receiver operating characteristic curve (AUC) values were 0.770, 0.759, and 0.671 in the training cohort, 0.809, 0.782, and 0.735 in the internal validation cohort, 0.786, 0.856, and 0.770 in the external validation cohort. Furthermore, calibration curves revealed that the expected and actual probabilities of CSD were relatively consistent. CONCLUSION: Stage I–II GNEC patients could not benefit from adjuvant chemotherapy after surgery. De-escalation of chemotherapy should be considered for stage I–II GNEC patients. The proposed nomogram exhibited excellent prediction ability. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-023-03029-2.
format Online
Article
Text
id pubmed-10163728
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101637282023-05-07 De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysis Du, Danwei Xie, Yangyang Li, Xiaowen Ni, Zhongkai Shi, Jinbo Huang, Hai World J Surg Oncol Research BACKGROUND: The role of adjuvant chemotherapy in gastric neuroendocrine neoplasms (GNEC) has not been well clarified yet. The study was designed to investigate the potential effect of adjuvant chemotherapy in stage I–II GNEC patients and construct a predictive nomogram. METHOD: Stage I–II GNEC patients were included in the Surveillance, Epidemiology, and End Results (SEER) database and divided into chemotherapy and no-chemotherapy groups. We used Kaplan–Meier survival analyses, propensity score matching (PSM), and competing risk analyses. The predictive nomogram was then built and validated. RESULTS: Four hundred four patients with stage I–II GNEC were enrolled from the SEER database while 28 patients from Hangzhou TCM Hospital were identified as the external validation cohort. After PSM, similar 5-year cancer-specific survival was observed in two groups. The outcomes of competing risk analysis indicated a similar 5-year cumulative incidence of cancer-specific death (CSD) between the two cohorts (35.4% vs. 31.4%, p = 0.731). And there was no significant relation between chemotherapy and CSD in the multivariate competing risks regression analysis (HR, 0.79; 95% CI, 0.48–1.31; p = 0.36). Furthermore, based on the variables from the multivariate analysis, a competing event nomogram was created to assess the 1-, 3-, and 5-year risks of CSD. The 1-, 3-, and 5-year area under the receiver operating characteristic curve (AUC) values were 0.770, 0.759, and 0.671 in the training cohort, 0.809, 0.782, and 0.735 in the internal validation cohort, 0.786, 0.856, and 0.770 in the external validation cohort. Furthermore, calibration curves revealed that the expected and actual probabilities of CSD were relatively consistent. CONCLUSION: Stage I–II GNEC patients could not benefit from adjuvant chemotherapy after surgery. De-escalation of chemotherapy should be considered for stage I–II GNEC patients. The proposed nomogram exhibited excellent prediction ability. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-023-03029-2. BioMed Central 2023-05-06 /pmc/articles/PMC10163728/ /pubmed/37149679 http://dx.doi.org/10.1186/s12957-023-03029-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Du, Danwei
Xie, Yangyang
Li, Xiaowen
Ni, Zhongkai
Shi, Jinbo
Huang, Hai
De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysis
title De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysis
title_full De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysis
title_fullStr De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysis
title_full_unstemmed De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysis
title_short De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysis
title_sort de-escalating chemotherapy for stage i–ii gastric neuroendocrine carcinoma? a real-world competing risk analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163728/
https://www.ncbi.nlm.nih.gov/pubmed/37149679
http://dx.doi.org/10.1186/s12957-023-03029-2
work_keys_str_mv AT dudanwei deescalatingchemotherapyforstageiiigastricneuroendocrinecarcinomaarealworldcompetingriskanalysis
AT xieyangyang deescalatingchemotherapyforstageiiigastricneuroendocrinecarcinomaarealworldcompetingriskanalysis
AT lixiaowen deescalatingchemotherapyforstageiiigastricneuroendocrinecarcinomaarealworldcompetingriskanalysis
AT nizhongkai deescalatingchemotherapyforstageiiigastricneuroendocrinecarcinomaarealworldcompetingriskanalysis
AT shijinbo deescalatingchemotherapyforstageiiigastricneuroendocrinecarcinomaarealworldcompetingriskanalysis
AT huanghai deescalatingchemotherapyforstageiiigastricneuroendocrinecarcinomaarealworldcompetingriskanalysis